When the tariff becomes the argument

According to CNBC, the United States Trade Representative has opened a formal probe targeting Germany's drug-pricing policies, with Jamieson Greer describing Berlin's proposals to reduce pharmaceutical spending as "a serious step backwards." One reads this and feels a familiar unease — not because the underlying grievance is wholly invented, but because the instrument chosen to address it is so perfectly calibrated to make the problem worse.

Let me grant the rational case. If one country's pricing regime effectively free-rides on the research costs borne by another country's consumers, there is a genuine distortion. American patients, one may infer, pay elevated prices partly because other wealthy nations bargain hard. That asymmetry is real and worth negotiating. The question is never whether the grievance exists but whether the tool selected for remedy serves the goal — or merely serves the impulse.

A tariff probe aimed at a trading partner's domestic health expenditure is a category error of the first order. Germany's pharmaceutical budget is a sovereign fiscal decision, shaped by its own system of social insurance and democratic politics. To treat it as an unfair trade practice is to assert that any nation which spends less than America on any input has somehow cheated. Carried to its conclusion, this logic would oblige every country to replicate American prices in every market — a proposition whose absurdity should be apparent without my belaboring it.

The deeper concern is architectural. At Bretton Woods, those of us around the table understood — sometimes painfully — that the alternative to deliberate cooperative design is not the free play of national self-interest producing happy outcomes; it is a sequence of retaliations that leaves everyone worse off. The 1930s had taught that lesson in blood and unemployment. Bilateral pressure, imposed unilaterally, corrodes the very multilateral institutions through which legitimate complaints about pricing, intellectual property, and market access might otherwise be resolved. When you reach for the tariff first, you spend credibility you will need later for the negotiation that actually matters.

I should be honest about what I do not know. The specific mechanics of the U.S. pharmaceutical market — the role of pharmacy benefit managers, the structure of patent exclusivity, the precise gap between American and German prices — are matters on which I defer to those with modern technical command. My claim is narrower: that the macroeconomic and diplomatic logic of unilateral trade coercion is as poor in 2026 as it was in 1930, regardless of the sector.

What would I actually recommend? Begin with the World Trade Organization's dispute settlement mechanism, imperfect as it has become (by inference, given the institution's well-documented difficulties in recent years). Pursue plurilateral agreements on reference pricing that bring Germany, France, Japan, and others to a common table — the approach that has at least the form of mutual consent. Domestic reform of drug pricing in America is, in any case, the more powerful lever; the cost differential is substantially a product of choices made in Washington, not Berlin. A tariff probe abroad is, in this light, a distraction from the harder domestic conversation.

The gravest economic errors are rarely made by people who intend harm. They are made by negotiators who fixate on the short-run bilateral score while the long-run cooperative architecture quietly comes apart beneath them. I wrote once that in the long run we are all dead — but I did not mean that the long run therefore doesn't matter. I meant that we cannot afford to wait for it to take care of itself.